Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Enphase Energy IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Enphase Energy Inc trades at $42.74 (market cap $5.59B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 24× Enphase Energy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.

ENPHVRTX
Market Cap
$5.59B$134.25B
Sector
TechnologyHealth
52-Week High
$72.33$529.65
52-Week Low
$26.12$376.62
Enterprise Value
$5.23B$128.37B

Returns comparison

Trailing returns across standard periods

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX